← Leaderboard
BBIO
Ticker
BBIO
Congressional Trades
14
by 1 members
Ticker Intelligence Brief
Who in Congress traded BBIO, when, and what happened after?
A ticker-first view for retail/data users: latest disclosure, largest range, disclosure lag, party flow, contracts, lobbying, and source-linked receipts.
Latest receipt
Gilbert Cisneros
BUY · 2026-05-11
Largest range
$1K – $15K
Gilbert Cisneros
Slowest filing
38d
Gilbert Cisneros
Best vs SPY
48.2%
Gilbert Cisneros
Buys
14
100%
Sells
0
0%
Total Volume
$112K
midpoint
Unique Traders
1
members
Party Breakdown
Democrats14 · 100%
Republicans0 · 0%
Party Trading Divergence
Democrat vs. Republican buy / sell pressure by monthHIGH DIVERGENCEBar length = total trades. Color = net sentiment — green = net buying, red = net selling. Months with no activity hidden.
Democrat ←
Month
→ Republican
2▲
Aug '25
—
2▲
Sep '25
—
6▲
Mar '26
—
2▲
Apr '26
—
2▲
May '26
—
Democrats14▲0▼Net buyers
vs
Republicans0▲0▼Neutral
Net buyingNet selling⚡ Party split
💼 Lobbying Filings
all →- 2026-04-20$420KBRIDGEBIO PHARMA INC.H.R.7148 - Consolidated Appropriations Act, 2026 Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Orphan drug policies General issues and provisions related to PBM Reform
- 2026-04-17$60KBRIDGEBIO PHARMAIssues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
- 2026-01-20$270KBRIDGEBIO PHARMA INC.Give Kids a Chance Act of 2025 - H.R. 1262; S 932 General issues and provisions related to PBM Reform ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies
- 2026-01-16$60KBRIDGEBIO PHARMAIssues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
- 2025-10-20$270KBRIDGEBIO PHARMA INC.Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Camerons Law - H.R. 1414 Tax Provisions in H.R. 1 - One Big Beautiful Bill Act - R&D tax credit, bonus depreciation, interest deduction Provisions related to PBM Reform in H.R. 1 - One Big Beautiful Bill Act PBM Reform Act - H.R. 4317 ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies Scientific EXPERT Act of 2025 - H.R. 1532; S. 822
- 2025-10-20$60KBRIDGEBIO PHARMAIssues related to pharmaceutical manufacturing, drug pricing, and orphan drugs.
- 2025-10-11$20KBRIDGEBIO PHARMAPBM Policy Reform. Prior authorization. Utilization management.
- 2025-07-30$20KBRIDGEBIO PHARMAPBM Policy Reform. Prior authorization. Utilization management.
- 2025-07-21$20KBRIDGEBIO PHARMAIssues related to pharmaceutical manufacturing, drug pricing, and orphan drugs.
- 2025-07-21$0BRIDGEBIO PHARMAPBM Policy Reform. Prior authorization. Utilization management.
Congressional Momentum
buy vs. sell pressureACCUMULATINGScore 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.
Last 30 Days
No trades
Last 90 Days
▲100
4 buys4 total0 sells
$32K buys · $0 sells
All-Time
▲100
14 buys14 total0 sells
$112K buys · $0 sells
Cumulative Net Position (buy vol − sell vol)
+$112K
2025-0814 trades plotted2026-05
Timing Fingerprint
filing delay vs. excess return over SPY · 12 tradesCongress avg +1.7% vs SPYEach dot = one disclosed trade. X-axis = days between trade and STOCK Act filing.Y-axis = return above (or below) SPY over the subsequent holding window. Upper-right = late filers who beat the market.
42% of trades beat SPYavg excess +1.7%avg delay 24d12 buys0 sellsBuySellOther· dot size ∝ trade size
Trade Activity Timeline
Congressional buys & sells by month · last 5 months w/ activity
25/08
25/09
26/03
26/04
26/05
BuysSellsOtherHigh-volume month
Seasonal Rhythm
Congress buy/sell pressure by month & yearEach cell = one calendar month. Green = net Congress buying, red = net selling. Intensity ∝ consensus strength. Hover for details.
Net buyingNet sellingNo trades · number = trade count
Peak buy month: Mar · Peak sell month: Jan
Congressional Conviction Timeline
net positioning · alpha track recordBULLISH14 buys0 sellscumulative α +20.4%5mo tracked
Monthly Net Flow (Buys − Sells)
Cumulative Excess Return on Congressional Buys vs SPY
All Disclosed Trades
| Date | Member | Action | Amount | Filing Delay | Receipt |
|---|---|---|---|---|---|
| 2026-05-11 | DGilbert Cisneros | BUY | $1K – $15K | 29d | receipt → |
| 2026-05-11 | DGilbert Cisneros | BUY | $1K – $15K | 28d | receipt → |
| 2026-04-29 | DGilbert Cisneros | BUY | $1K – $15K | 12d | receipt → |
| 2026-04-29 | DGilbert Cisneros | BUY | $1K – $15K | 9d | receipt → |
| 2026-03-19 | DGilbert Cisneros | BUY | $1K – $15K | 20d | receipt → |
| 2026-03-18 | DGilbert Cisneros | BUY | $1K – $15K | 21d | receipt → |
| 2026-03-03 | DGilbert Cisneros | BUY | $1K – $15K | 36d | receipt → |
| 2026-03-19 | DGilbert Cisneros | BUY | $1K – $15K | 19d | receipt → |
| 2026-03-18 | DGilbert Cisneros | BUY | $1K – $15K | 20d | receipt → |
| 2026-03-03 | DGilbert Cisneros | BUY | $1K – $15K | 35d | receipt → |
| 2025-09-22 | DGilbert Cisneros | BUY | $1K – $15K | 21d | receipt → |
| 2025-09-22 | DGilbert Cisneros | BUY | $1K – $15K | 18d | receipt → |
| 2025-08-08 | DGilbert Cisneros | BUY | $1K – $15K | 38d | receipt → |
| 2025-08-08 | DGilbert Cisneros | BUY | $1K – $15K | 35d | receipt → |